{"organizations": [], "uuid": "dcd6da79605eafd7e22be7896392049a696e82f7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/23/globe-newswire-seamus-fernandez-to-join-guggenheim-securities-as-pharmaceuticals-analyst.html", "country": "US", "domain_rank": 767, "title": "Seamus Fernandez to Join Guggenheim Securities as Pharmaceuticals Analyst", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.003, "site_type": "news", "published": "2018-03-23T18:30:00.000+03:00", "replies_count": 0, "uuid": "dcd6da79605eafd7e22be7896392049a696e82f7"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/23/globe-newswire-seamus-fernandez-to-join-guggenheim-securities-as-pharmaceuticals-analyst.html", "ord_in_thread": 0, "title": "Seamus Fernandez to Join Guggenheim Securities as Pharmaceuticals Analyst", "locations": [], "entities": {"persons": [{"name": "seamus fernandez", "sentiment": "negative"}, {"name": "fernandez", "sentiment": "none"}, {"name": "seamus", "sentiment": "none"}, {"name": "leerink", "sentiment": "none"}, {"name": "stefano natella", "sentiment": "none"}], "locations": [{"name": "new york", "sentiment": "none"}, {"name": "leerink partners", "sentiment": "none"}], "organizations": [{"name": "guggenheim securities as pharmaceuticals analyst", "sentiment": "negative"}, {"name": "guggenheim securities", "sentiment": "negative"}, {"name": "department of neurosurgery", "sentiment": "none"}, {"name": "university of pennsylvania", "sentiment": "none"}, {"name": "equity research", "sentiment": "none"}, {"name": "cowen and company’s research division", "sentiment": "none"}, {"name": "guggenheim partners", "sentiment": "none"}, {"name": "healthcare research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Seamus Fernandez will join the firm in June as a Senior Analyst and Senior Managing Director in a planned expansion of the firm’s Healthcare Research team. He will focus on companies in the pharmaceuticals industry globally and coordinate the firm’s research coverage of therapeutics.\nMr. Fernandez joins Guggenheim from LEERINK Partners, where he spent more than 10 years and served as a Managing Director covering major pharmaceutical and biotechnology companies, as well as specialty pharmaceuticals. Previous to joining LEERINK in 2006, he was a member of the Pharmaceuticals team at Cowen and Company’s Research Division. Mr. Fernandez began his career as a Research Associate at the University of Pennsylvania’s Department of Neurosurgery.\n“We are excited for Seamus to join our Healthcare Research team,” said Stefano Natella, Director of Equity Research. “His deep industry knowledge, his ability to focus on the long-term issues driving this sector, and his differentiated approach to research will be key assets for our expanding research department. We look forward to his continued success at Guggenheim.”\nMr. Fernandez received his B.A. in Chemistry from Williams College.\nAbout Guggenheim Securities\nGuggenheim Securities is the investment banking and capital markets business of Guggenheim Partners, a global investment and advisory firm. Guggenheim Securities offers services that fall into four broad categories: Advisory, Financing, Sales and Trading, and Research. Guggenheim Securities is headquartered in New York, with additional offices in Chicago, Boston, Atlanta, Los Angeles, San Francisco, and Houston. For more information, please contact us at GSinfo@GuggenheimPartners.com or 212.518.9200.\nAbout Guggenheim Partners\nGuggenheim Partners is a global investment and advisory firm with more than $305 billion1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With over 2,300 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs .\n1 Assets under management are as of 12.31.2017 and include consulting services for clients whose assets are valued at approximately $66bn.\nMedia Contact\nEllen Cunningham\nGuggenheim Partners\n212.518.9578\nEllen.N.Cunningham@GuggenheimPartners.com\nSource:Guggenheim Securities", "external_links": ["http://twitter.com/guggenheimptnrs", "https://www.globenewswire.com/Tracker?data=hABmGPeDcVI9qgQqlPu0H_mVlKKa062WSuAHafRK0QGJZUAdc8v5uKTaL6jkcaUkdH4YeT7H06IbFlY8dMeDybRb_4qVKK8BSU-Gp7_QXnsBDnAUZ_xNDfwTeWLko2xHwZF-DD2CoVvEJ2KwEbzPLA=="], "published": "2018-03-23T18:30:00.000+03:00", "crawled": "2018-03-23T19:40:11.000+03:00", "highlightTitle": ""}